On August 9, the 2022 World Conference on Lung Cancer (WCLC) concluded in Vienna, the capital of Austria. Professor ZHOU Caicun, director of the Department of oncology of Shanghai Lung Hospital Affiliated to Tongji University and director of the Institute of Oncology of Tongji University Medical School, won the Cancer Care Team Award issued by the International Association for the Study of Lung Cancer (IASLC), becoming the only Asian team among the four award-winning teams in the world this year.

ZHOU Caicun’s team winning the Cancer Treatment Team Award

The Cancer Treatment Team Award is publicly selected by IASLC in the world every year to commend the multidisciplinary treatment team of lung cancer that has made outstanding contributions in lung cancer treatment and won international recognition.

Professor ZHOU Caicun's team is committed to the research of targeted therapy, anti-vascular therapy, immunotherapy and clinical transformation of lung cancer. He led the team to establish and improve the method of obtaining small samples of lung cancer and the rapid detection path of molecular typing in China. For the lung cancer patients treated in the Shanghai Pulmonary Hospital, it takes only 4 working days from the initial diagnosis to the establishment of a treatment plan.

Professor ZHOU Caicun (middle) looking up his patient

Professor ZHOU Caicun (fifth from the front left) and his team

From the establishment of his Lung Cancer laboratory, capacity building of the team, to the improvement of the lung cancer treatment process, ZHOU’s team has made unremitting efforts for nearly ten years. This award is the second time that the lung cancer diagnosis and treatment system with the Shanghai Pulmonary Hospital was recognized by its international peers. It also showed that the diagnosis and treatment of advanced lung cancer in China has been in the forefront of the world.

Remarks on ZHOU Caicun's team by their international peers

ZHOU Caicun's team has become one of the most important clinical research teams in China. As the PI (main research team leader unit) of more than 30 international and domestic centers registered for clinical trials, the team has participated in more than 50 clinical studies. It has undertaken more than 20 projects including the National 863 program, programs funded by the National Natural Science Foundation, major research projects of Shanghai Municipal Science and Technology Commission, and the Shenkang New Frontier Project. He has published more than 400 papers in domestic and international journals, edited and translated a number of academic monographs, and won invention patents. He won the second prize of the Chinese Medical Science and Technology Award, the first prize of the Huaxia Medical Science and Technology Award, the first prize of the Science and Technology Award of the Chinese Cancer Association, the first prize of the Shanghai Science and Technology Progress Award and the second prize of the National Science and Technology Progress Award.